PI3K inhibitors for cancer therapy: what has been achieved so far?

@article{Wu2009PI3KIF,
  title={PI3K inhibitors for cancer therapy: what has been achieved so far?},
  author={Peng Wu and Tao Liu and Yongzhou Hu},
  journal={Current medicinal chemistry},
  year={2009},
  volume={16 8},
  pages={
          916-30
        }
}
PI3K is a large duel lipid and protein kinase that catalyzes phosphorylation of the 3-hydroxyl position of phosphatidylinositides (PIs) and plays a crucial role in the cellular signaling network. Inhibition of the phosphatidylinositol 3-kinase (PI3K) signaling pathway is a newly identified strategy for the discovery and development of certain therapeutic agents. Among the various subtypes of PI3K, class IA PI3Kalpha has gained increasing attention as a promising drug target for the treatment of… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…